More and more people are talking about Centene over the last few weeks. Is it worth buying the Medical Specialities stock at a price of $66.52? Only time will tell. The information below will give you a basic idea of what this investment may entail:
-
Centene has moved -24.0% over the last year, and the S&P 500 logged a change of -5.4%
-
CNC has an average analyst rating of buy and is -24.88% away from its mean target price of $88.55 per share
-
Its trailing earnings per share (EPS) is $2.07
-
Centene has a trailing 12 month Price to Earnings (P/E) ratio of 32.1 while the S&P 500 average is 15.97
-
Its forward earnings per share (EPS) is $7.07 and its forward P/E ratio is 9.4
-
The company has a Price to Book (P/B) ratio of 1.5 in contrast to the S&P 500's average ratio of 2.95
-
Centene is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
-
The company has a free cash flow of $3,337,250,048.00, which refers to the total sum of all its inflows and outflows of cash over the last quarter
-
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. It operates in two segments, Managed Care and Specialty Services.
